Physician profile
Deepa Limaye
NPI 1093777948
$5,092.47
in general payments reported to CMS, 2019-2025
24 companies · $899 in 2025
The $899 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $484 · 2021: $866 · 2022: $540 · 2023: $729 · 2024: $1,158 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,785.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $982.01 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $954.45 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $759.30 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $585.31 | 2020-2025 | Dyanavel Xr, Onyda Xr, Quillichew Er |
| Takeda Pharmaceuticals U.S.A., INC. | $204.80 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $181.96 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $171.91 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Adlon Therapeutics L.P. | $151.14 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $148.50 | 2024-2025 | Relexxii |
| Pfizer INC. | $118.10 | 2019-2020 | |
| Glaxosmithkline, LLC. | $104.81 | 2019-2024 | Bexsero, Rotarix |
| Sobi, INC | $102.45 | 2019-2023 | |
| Rhodes Pharmaceuticals L.P. | $90.86 | 2019 | |
| Seqirus USA INC | $85.50 | 2022-2023 | Flucelvax Quadrivalent |
| Shire North American Group INC | $66.80 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $65.74 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $65.47 | 2021-2025 | Ultomiris |
| Phadia US INC. | $51.34 | 2019-2022 | |
| Cranial Technologies, INC | $44.30 | 2022-2024 | Doc Band |
| Sanofi-Aventis U.S. LLC | $38.47 | 2025 | |
| Neos Therapeutics, Lp | $34.47 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $32.94 | 2024-2025 | Zoryve |
| Ars Pharmaceuticals Operations, INC. | $26.71 | 2025 | Neffy |
| Acadia Pharmaceuticals INC | $25.13 | 2025 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Limaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.